Tag Archives | News Releases

IntegenX Announces ISO 9001:2008 Certification

IntegenX® has been awarded the ISO 9001:2008 certification for the design, development, manufacture, and distribution of automated DNA identification systems

PLEASANTON, California – March 31, 2014 – IntegenX Inc., the market leader in Rapid Human DNA identification, announced today that it has earned ISO 9001:2008 certification for its quality management system for the design, development, manufacture and distribution of automated DNA identification systems. IntegenX manufactures the RapidHIT® System for human identification and is the first company in the rapid DNA market to achieve such a standard.

“Meeting a high quality standard is a priority for everyone at IntegenX,” said David V. Smith, Chief Operating Officer. “Fulfilling the stringent requirements of the ISO 9001:2008 standard is part of our effort to deliver total customer satisfaction as it relates to quality.”

ISO 9001:2008 is a quality management system standard developed by the International Organization for Standardization, an association of governmental and nongovernmental organizations from 163 countries that develops international standards. The ISO 9001:2008 standard is used to certify quality management systems that focus on customer satisfaction, continuous improvement, active involvement of senior management and employees, and the adoption of a process approach. Certification under ISO 9001:2008 implies customers will benefit from products that are robust and reliable, readily available meeting international regulatory standards.

“Earning certification is a significant accomplishment by our employees’, reflecting their commitment and hard work,” commented Robert A. Schueren, President, Chief Executive Officer. “Our customers expect exceptional products that also adhere to the highest standards of quality and performance.”

About IntegenX

IntegenX, headquartered in Pleasanton, California, is the market leader of Rapid human DNA identification technology. IntegenX technology platforms integrate advanced fluidics, optics, and biochemistry capabilities to produce sample-to-answer products for DNA-based human identity testing for forensics and law enforcement applications. For more information, please visit www.integenx.com.

IntegenX, the IntegenX logo, and RapidHIT are trademarks of IntegenX Inc. All other names or trademarks are the property of their respective owners.

###
Contact:
David V. Smith
Chief Operating Officer
IntegenX Inc.
5720 Stoneridge Drive, Suite 300
Pleasanton, CA 94588
925.701.3400

IntegenX Announces Approval to Upload DNA Profiles from the RapidHIT® System to the National Database

The RapidHIT System is the first rapid DNA technology that uses FBI-approved GlobalFiler® Express chemistry, enabling the upload of DNA profiles to the National DNA Index System (NDIS)

PLEASANTON, California – March 13, 2014 – IntegenX Inc., the market leader in Rapid Human DNA identification, has met the FBI guidelines to upload data to the NDIS system, after forensic review, of known arrestee and convicted offender DNA profiles, as well as casework known samples, generated with the RapidHIT System using Life Technologies GlobalFiler Express kits from Thermo Fisher Scientific.

The RapidHIT GlobalFiler Express cartridges contain Life Technologies NDIS-approved GlobalFiler Express Kit, which has all DNA markers commonly used in most international databases. NDIS is considered one part of Combined DNA Index System (CODIS), the national level containing the DNA profiles contributed by federal, state, and local participating forensic laboratories. CODIS is the generic term used to describe the FBI’s program of support for criminal justice DNA databases as well as the software used to run these databases.

“Having the ability to upload a profile into the national database from a Rapid DNA system provides laboratories with an excellent option for turning results around quickly” commented Gray Amick, Ph.D., DNA Technical Leader at Richland County Sheriff’s Department. “In our continued quest to reduce time to generating results, the RapidHIT System provides a great option.”

“For the first time ever, an accredited forensic laboratory can upload a DNA profile from a Rapid DNA system in less than two hours, into our national database,” commented Robert A. Schueren, president, chief executive officer, IntegenX. “We’re thrilled to be the first and only company to achieve such a milestone”.

“The GlobalFiler Express chemistry has proven to be a transformative solution for forensic labs since first introduced in 2012 and approved by the FBI a year later,” said Nadia Altomare, vice president and general manager, Human Identification, for Thermo Fisher Scientific. “The speed and superior quality of data obtained by our solution expedites comparison of DNA profiles to help solve and prevent crimes faster.”

With less than five minutes of hands-on time, the RapidHIT system enables buccal swabs collected from known arrestees and convicted offenders, as well as casework known samples to be analyzed in less than two hours, compared to weeks or months with conventional laboratory techniques, dramatically improving efficiency of forensic laboratories. This improved efficiency will allow laboratories to spend more time reducing backlog and processing other forensic samples. The innovative design of the Life Technologies GlobalFiler Express cartridges allows users to process between one and seven samples in a single run, offering further savings to forensic laboratories.

RapidHIT System DNA profiles are completely compatible with standard databases that contain previously generated profiles from buccal swabs and crime scene sources. Combining ease of use and rapid turnaround time for DNA human identification will have a high impact toward ensuring the safety of our communities.

More information about the ability to utilize Rapid DNA technology with NDIS may be found at http://www.fbi.gov/about-us/lab/biometric-analysis/codis/codis-and-ndis-fact-sheet

About IntegenX Inc.
IntegenX, headquartered in Pleasanton, California, is the market leader of Rapid human DNA identification technology. IntegenX technology platforms integrate advanced fluidics, optics, and biochemistry capabilities to produce sample-to-answer products for DNA-based human identity testing for forensics and law enforcement applications. For more information, please visit www.integenx.com.
IntegenX, the IntegenX logo, and RapidHIT are trademarks of IntegenX Inc. All other names or trademarks are the property of their respective owners.

###
Contact:
David V. Smith
Chief Operating Officer
IntegenX Inc.
5720 Stoneridge Drive, Suite 300
Pleasanton, CA 94588
925.701.3400

IntegenX Launches New GlobalFiler® Express Cartridges for RapidHIT® System at the American Academy of Forensic Sciences (AAFS) Meeting

IntegenX has completed the Developmental Validation of GlobalFiler Express reagents from Life Technologies on the RapidHIT System in accordance with SWGDAM guidelines

PLEASANTON, California – February 18, 2014 – IntegenX Inc., the market leader in Rapid Human DNA identification technology, today announced the launch of GlobalFiler® Express cartridges for the RapidHIT™ System, providing DNA profiles with 24-loci in less than two hours with less than five minutes hands-on time. The RapidHIT GlobalFiler Express cartridges contain Life Technologies’ NDIS-approved GlobalFiler Express Kit which has all DNA markers commonly used in most international databases, including all markers recommended for inclusion by the CODIS Core Loci Working Group. The RapidHIT GlobalFiler Express cartridges feature a flexible design, allowing operators to run from one to seven samples in a single run, as well as a room temperature cartridge storage protocol.

IntegenX completed the Developmental Validation of the GlobalFiler Express cartridges with the RapidHIT System for buccal swabs with a highly successful CODIS profile generation rate. Completion of Scientific Working Group for DNA Analysis Methods (SWGDAM) Developmental Validation is a key milestone necessary for the commercialization of human DNA identification systems in forensics, law enforcement, defense, homeland security, and intelligence community applications: the RapidHIT is the only Rapid DNA System to have met such a milestone.

In addition to Developmental Validation data for buccal swabs, IntegenX has generated data demonstrating the RapidHIT System readily analyzes samples routinely recovered from crime scenes, such as blood, saliva, and semen. These applications dramatically expand the utility of the RapidHIT System and provide a fast DNA-based crime scene investigation and rapid lead identification capability for the law enforcement, defense, and intelligence communities worldwide. Data will be presented at the 66th Annual AAFS meeting, February 17-22, Seattle, Washington.

“The combination of the extremely high discrimination power of the large GlobalFiler Express multiplex and the capability of an expedited sample-to-answer with RapidHIT DNA technology should be a powerful tool to extend the utility of DNA typing both outside and within the laboratory,” said Bruce Budowle, Ph.D., executive director of the Institute of Applied Genetics at the University of North Texas Health Science Center (UNTHSC).

“We’re thrilled at the full commercial global launch of the RapidHIT GlobalFiler Express cartridges, and the new flexible format that allows operators to decide how many samples to include per run. The Developmental Validation of the GlobalFiler Express cartridges under SWGDAM guidelines is an important milestone. Offering Life Technologies’ most advanced NDIS-approved chemistry on the RapidHIT will be of great value to the US and worldwide forensic communities,” commented Robert Schueren, president and chief executive officer of IntegenX.

“The superior quality of the data obtained from GlobalFiler Express kits has proven to be a transformative solution for forensic labs,” said Nadia Altomare, vice president and general manager, Human Identification, for Thermo Fisher Scientific. “Our partnership with IntegenX brings together the industry’s most powerful chemistry and the leading rapid platform to help forensic laboratories and law enforcement agencies solve and prevent crimes.”

The IntegenX RapidHIT System fully automates and integrates all steps necessary to generate a DNA profile in less than two hours. With less than five minutes of hands-on time, an operator can generate up to seven complete DNA profiles. RapidHIT System DNA profiles are completely compatible with standard databases that contain previously generated profiles from reference and crime scene sources. Combining ease of use and rapid turnaround time for DNA human identification will have a high impact toward ensuring the safety of our communities.

About IntegenX Inc.
IntegenX, headquartered in Pleasanton, California, is the market leader of Rapid human DNA identification technology. IntegenX technology platforms integrate advanced fluidics, optics, and biochemistry capabilities to produce sample-to-answer products for DNA-based human identity testing for forensics and law enforcement applications. For more information, please visit www.integenx.com.
IntegenX, the IntegenX logo, and RapidHIT are trademarks of IntegenX Inc. All other names or trademarks are the property of their respective owners.

###
Contact:
David V. Smith
Chief Operating Officer
IntegenX Inc.
5720 Stoneridge Drive, Suite 300
Pleasanton, CA 94588
925.701.3400

IntegenX RapidHIT™ to Star in November 6th episode of CSI: Crime Scene Investigation

Rapid DNA technology featured on CSI: Crime Scene Investigation is being utilized by forensic labs and law enforcement agencies worldwide

PLEASANTON, California – November 5, 2013 – IntegenX Inc., the leading developer of Rapid DNA human identification technology, today announced that the RapidHIT™ System will be starring in the November 6th episode of the long-running, forensic science-based television show CSI: Crime Scene Investigation. In episode 7, “Under A Cloud”, investigators will be racing against the clock to track a perpetrator, with the RapidHIT System as a critical technology to solve the crime.

CSI: Crime Scene Investigation writers make great efforts to research the latest cutting-edge forensic tools and technologies and ensure the show is representing the latest innovations. In episode 7, the RapidHIT System is deployed in a mobile crime scene vehicle, an actual scenario at a major law enforcement agency today. According to Sheila Thomas, Product Integration Specialist for the show, “Our technical advisors were contacted by various law enforcement agencies about the RapidHIT System. It’s simple to use, providing accurate results in 90 minutes. Without the RapidHIT System we could not have developed the storyline.”

While the story is fictional, the commercially available RapidHIT System is helping law enforcement agencies solve real crimes around the world. The RapidHIT System fully automates and integrates all steps necessary to generate a DNA profile with less than five minutes of hands-on time. “We’re thrilled that the producers have chosen to premiere the RapidHIT on their show. It’s a testament to the system’s ability to combine ease of use with rapid turnaround time providing an invaluable impact toward solving crimes quickly, and ensuring the safety of communities worldwide”, commented Robert Schueren, President, Chief Executive Officer of IntegenX.

About IntegenX Inc.
IntegenX, headquartered in Pleasanton, California, is a leading developer of rapid human DNA identification technology. IntegenX technology platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce sample-to-answer products for DNA-based human identity testing, forensics, and biodefense applications. For more information, please visit www.integenx.com.

IntegenX, the IntegenX logo, and RapidHIT are trademarks of IntegenX Inc. All other names or trademarks are the property of their respective owners.

###

Contact:

David V. Smith
Chief Operating Officer
IntegenX Inc.
5720 Stoneridge Drive, Suite 300
Pleasanton, CA 94588
925.701.3400

IntegenX Presents Developmental Validation Data and End-User Evaluations of the RapidHIT System at the 24th International Symposium on Human Identification (ISHI24)

The RapidHIT System is the world’s first rapid DNA technology to complete developmental validation in accordance with SWGDAM guidelines, and achieve full global commercial launch

PLEASANTON, California – October 9, 2013 – IntegenX Inc., the leading developer of rapid human DNA identification technology, today announced that it presented the latest data on developmental validation of the RapidHIT™ System as outlined by SWGDAM (Scientific Working Group for DNA Analysis Methods) at the 24th International Symposium on Human Identification (ISHI 24) in Atlanta, GA, October 7–10, 2013.

The RapidHIT System is the first fully automated rapid human DNA identification system to complete developmental validation in accordance with SWGDAM guidelines. Completion of developmental validation is necessary for full commercialization of rapid DNA technologies for human identification in forensics, law enforcement, defense, homeland security, and intelligence community applications.

At the ISFG (International Society for Forensic Genetics) meeting in early September 2013, IntegenX provided previews of RapidHIT developmental validation data, including successful generation of CODIS profiles. Later in September, at the Biometric Consortium Conference, an inter-lab study conducted by a third-party group was presented, showing that the RapidHIT System outperformed other methods in categories including CODIS loci success rate, peak height ratio, and stutter.

“Overall, the RapidHIT System outperformed traditional capillary electrophoresis based methods in producing useable profile information on a first-pass basis. General observations included 100% concordance with known profiles, similar performance after two weeks of sample storage, and an absence of chamber-to-chamber or run-to-run contamination,” said Dr. Mitchell Holland, Director, Forensic Science, Pennsylvania State University.

At ISHI 24, IntegenX unveiled additional developmental validation data and shared evaluations of the RapidHIT System by end users at a workshop, “Making a Difference in Minutes – RapidHIT System Developmental Validation and End-User Evaluations for Rapid Human Identification.” The company also presented data on the ability of the system to rapidly generate DNA profiles from a variety of biological samples, such as blood and saliva, which are routinely recovered from crime scenes. Data on integration of a European STR assay on the system were also showcased.

“We continue to build upon the exceptional number of studies and outcomes with the RapidHIT System. The data continue to represent the level of performance any forensic lab has come to expect,” commented Robert Schueren, President and Chief Executive Officer of IntegenX.

These latest advances of the RapidHIT System dramatically expand its utility for use in crime scene investigation and rapid lead identification, enabling forensics and law enforcement personnel to quickly link a suspect’s DNA to a crime scene, or eliminate suspicion, while the suspect is still in custody.

The RapidHIT System fully automates and integrates all steps necessary to generate a DNA profile in approximately 90 minutes. With less than five minutes of hands-on time, a user can generate up to five complete DNA profiles, as well as a positive and negative control. DNA profiles generated by the RapidHIT System are compatible with standard databases that contain previously generated profiles from reference and crime scene sources. Combining ease of use and rapid turnaround time for DNA results will have a high impact toward ensuring the safety of our communities.

About IntegenX Inc.
IntegenX, headquartered in Pleasanton, California, is a leading developer of rapid human DNA identification technology. IntegenX technology platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce sample-to-answer products for DNA-based human identity testing, forensics, and biodefense applications. For more information, please visit www.integenx.com.

IntegenX, the IntegenX logo, and RapidHIT are trademarks of IntegenX Inc. All other names or trademarks are the property of their respective owners.

###

Contact:

David V. Smith
Chief Operating Officer
IntegenX Inc.
5720 Stoneridge Drive, Suite 300
Pleasanton, CA 94588
925.701.3400

 

IntegenX to Present Significant Advances in Rapid DNA Technology at the 25th World Congress of the International Society of Forensic Genetics (ISFG)

The RapidHIT System is the world’s first rapid DNA technology to complete developmental validation in accordance with SWGDAM guidelines, and achieve full global commercial launch

PLEASANTON, California – September 2, 2013 – IntegenX Inc., the leading developer of rapid human DNA identification technology, today announced that it has completed developmental validation for the RapidHIT™ System, the first fully automated, fully integrated rapid human DNA identification system. Data will be presented at the 25thWorld Congress of the International Society of Forensic Genetics in Melbourne, Australia, September 2-7, 2013.

Completion of SWGDAM (Scientific Working Group for DNA Analysis Methods) developmental validation is a key milestone necessary for the full commercialization of DNA technologies for the purposes of human identification in forensics, law enforcement, defense, homeland security, and intelligence community applications. In addition to developmental validation data including highly successful CODIS profile generation, IntegenX will present data on the use of the RapidHIT System to analyze samples routinely recovered from crime scenes, such as blood and saliva. These applications dramatically expand the utility of the RapidHIT System for use in crime scene investigation and rapid lead identification by law enforcement, defense, and the intelligence community. The ability to rapidly generate DNA profiles on a variety of biological samples fundamentally changes the way investigations are conducted by enabling forensics and law enforcement personnel to quickly link a suspect’s DNA to a crime scene, or eliminate suspicion, all while the suspect is still in custody.

“The completion of a developmental validation study by the manufacturer is a critical important step toward establishing rapid DNA technology as reliable and robust. Rapid DNA technology will enable both forensic and law enforcement professionals to expand the use of DNA typing as a tool to solve crimes,” said Dr. Bruce Budowle, Professor, Executive Director of the Institute of Applied Genetics at the University of North Texas Health Science Center.

“We’re thrilled at the full commercial launch of the RapidHIT System, and the significant validation dataset we have been able to generate. We look forward to helping communities and governments throughout the world implement such a game changing technology,” commented Robert Schueren, President and Chief Executive Officer of IntegenX.

The IntegenX RapidHIT System fully automates and integrates all steps necessary to generate a DNA profile in approximately 90 minutes. With less than five minutes of hands-on time, a user can generate up to five complete DNA profiles, as well as a positive and negative control. DNA profiles generated by the RapidHIT System are compatible with standard databases that contain previously generated profiles from reference and crime scene sources. Combining ease of use and rapid turnaround time for DNA results will have a high impact toward ensuring the safety of our communities.

About IntegenX Inc.
IntegenX, headquartered in Pleasanton, California, is a leading developer of rapid human DNA identification technology. IntegenX technology platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce sample-to-answer products for DNA-based human identity testing, forensics, and biodefense applications. For more information, please visit www.integenx.com.

IntegenX, the IntegenX logo, and RapidHIT are trademarks of IntegenX Inc. All other names or trademarks are the property of their respective owners.

###

Contact:

David V. Smith
Chief Operating Officer
IntegenX Inc.
5720 Stoneridge Drive, Suite 300
Pleasanton, CA 94588
925.701.3400

 

IntegenX Names Robert A. Schueren Chief Executive Officer

PLEASANTON, Calif. – April 17, 2013 – IntegenX Inc., a privately held company and leading developer of rapid human DNA identification technology, DNA sequencing library preparation systems, and DNA/RNA ambient temperature stability and storage products, today announced the appointment of Robert A. Schueren as Chief Executive Officer.

Robert A. Schueren has nearly 30 years of commercial and operational experience, and has held leadership positions in life science companies for more than two decades. Most recently, he was Vice President and General Manager, Genomics, for Agilent Technologies. Prior to joining Agilent in 2010, he was the Global Head of Clinical Biomarkers and Operations and Deputy Global Head of Molecular Medicine Labs for Genentech, Inc., a company he joined in 2006. While at Genentech, Mr. Schueren held increasingly responsible positions including Senior Director, Development Sciences and Director Companion Diagnostics. Prior to Genentech, Mr. Schueren was the Executive Vice President and Chief Operating Officer of Arcturus Bioscience from 2003 to 2006. From 1997 to 2002, Mr. Schueren held leadership positions with Accumetrics. He also held commercial positions with Biosite Diagnostics and Gen-Probe, Inc.

“IntegenX is uniquely positioned to lead the revolution in how rapid DNA is applied—one that will transform law enforcement, intelligence and border control. For the first time, rapid DNA profiles will be included in the arsenal of actionable information used for human identification and to strengthen criminal and terrorist investigations.” said Mr. Schueren. “I am excited to participate in this new revolution and look forward to working with the IntegenX team as we drive the development of the significant new markets rapid DNA creates.”

Stevan Jovanovich, Ph.D., a founder and past President and CEO of IntegenX, will remain with the Company as Chief Technology Officer.

“We are delighted to have Bob join the company. His significant commercial and operations experience at companies such as Agilent and Genentech will prove invaluable as IntegenX commercializes its rapid human DNA identification system,” commented Dr. David Barker, Chairman of the Board of IntegenX. “The board is also very pleased that Stevan will assume the role of Chief Technology Officer, where he will continue to play a critical part in building the success of the Company.”

About IntegenX Inc.
IntegenX, headquartered in Pleasanton, California, is a leading developer of rapid human DNA identification technology, next-generation sequencing library preparation systems, and DNA/RNA ambient temperature stability and storage products. IntegenX technology platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce sample-to-answer products for DNA-based human identity testing and forensics, next generation sequencing, and biodefense applications. The company’s expertise and extensive intellectual property includes its patented MOVe™ valve technology, patent-pending PrepX™ reagent kits for next generation sequencing library preparation, as well as a portfolio of patented DNA and RNA reagents including GenTegra™ for stabilization and storage of purified DNA and RNA, and GenPlate® for storage of blood samples. For more information, please visit www.integenx.com.

IntegenX, the IntegenX logo, PrepX, MOVe, GenTegra, GenPlate and RapidHIT are trademarks of IntegenX Inc. All other names or trademarks are the property of their respective owners.

 

###

 

Contact:

David V. Smith
Chief Operating Officer
IntegenX Inc.
5720 Stoneridge Drive, Suite 300
Pleasanton, CA 94588
925.701.3400

IntegenX Teams with SAIC to Pursue Defense Threat Reduction Agency Contracts Using Rapid DNA Biometrics Capability

Fast DNA Analysis Yields Tactical Advantages in the Field

Pleasanton, CA — February 26, 2013 — IntegenX and Science Applications International Corporation (SAIC) announced today that they have signed a teaming agreement to pursue Defense Threat Reduction Agency (DTRA) Indefinite Delivery/Indefinite Quantity (ID/IQ) Awards supporting U.S. needs for detection of weapons of mass destruction. Support provided by IntegenX and SAIC will enable warfighters to complete their missions efficiently and effectively by supplying an integrated system that provides rapid DNA-based identification of biothreat agents.

Rapid DNA analysis is a transformative technology set to fundamentally change the way investigations are conducted by enabling the rapid and definitive identification of bioagents. Rapid DNA technology has the potential to help protect communities through quick detection of biothreat agents and to provide world class DNA identification capabilities to field forward personnel.

In 2012, IntegenX successfully participated in an invitation-only U.S. Department of Defense (DOD) exercise where its RapidHIT™ 200 Human DNA Identification System repeatedly delivered accurate human DNA profiles from swabs, bottles, cans, sputum, hair, saliva and blood. The RapidHIT 200 is a mobile, self-contained DNA identification system that automates and accelerates the process of producing standardized DNA profiles from samples in less than 90 minutes. The teaming agreement pairs SAIC’s biodefense capabilities with IntegenX’s rapid DNA technologies. IntegenX will leverage its RapidHIT System as part of the agreement and SAIC will integrate its software and biodefense capability with the RapidHIT to customize the system for detection of biothreats.

“The RapidHIT System will allow for rapid DNA analysis at the point of action, setting a new standard in the usage of DNA profiles to detect and identify bioagents down to the sub-species level in less than 90 minutes,” said Stevan Jovanovich, Ph.D., President and Chief Executive Officer of IntegenX. “Teaming with SAIC will give the U.S. government further access to IntegenX’s rapid DNA technology. SAIC has shown that they can integrate complex software and detection modalities for support of military biodefense applications.”

About IntegenX Inc.

IntegenX, headquartered in Pleasanton, California, is a leading developer of rapid human DNA identification technology. IntegenX technology platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce sample-to-answer products for DNA-based human identity testing, forensics, and biodefense applications. For more information, please visit www.integenx.com.

IntegenX, the IntegenX logo, and RapidHIT are trademarks of IntegenX Inc. All other names or trademarks are the property of their respective owners.

Former Senior FBI Official Louis E. Grever Joins IntegenX™ Board of Directors

PLEASANTON, CA – March 28, 2012 – IntegenX Inc., a privately held company that is leading the emerging field of rapid human DNA identification, today announced that Louis E. Grever, former Executive Assistant Director, Science and Technology Branch of the Federal Bureau of Investigation (FBI), has joined the company’s Board of Directors.

“Rapid DNA analysis is a transformative technology that will fundamentally change the way investigations are conducted by enabling law enforcement personnel to quickly and definitively identify suspects while they are in custody,” said Mr. Grever. “I believe this technology will create safer communities through its many applications from policing to homeland security and defense. I look forward to working with IntegenX as they introduce the first rapid DNA systems to the market this year.”

Mr. Grever recently retired from a 24-year career with the FBI. He began as a Special Agent in 1988, and was promoted to a series of positions of increasing responsibility throughout his tenure. Upon the formation of the new FBI Science and Technology Branch (STB) in 2006, Mr. Grever was assigned to the Office of the Director and served as the first Special Assistant to the STB Executive Assistant Director. In 2007, he was promoted to Deputy Assistant Director and placed in charge of the Special Technologies and Applications Office, a new entity within the STB authorized to develop and deploy innovative technical and analytical tools and capabilities for the FBI. Later in 2007, Mr. Grever was selected as the deputy to the STB Executive Assistant Director. In October 2008, he was appointed by the Director to serve as the STB Executive Assistant Director. In this role, Mr. Grever was responsible for all of the FBI’s forensic, biometric, and applied technology support to law enforcement delivered by the FBI Laboratory, Criminal Justice Information Services, and Operational Technology Divisions.

“Louis was instrumental in introducing the FBI’s Rapid DNA Initiative and in setting a vision for DNA as a fast identification tool to aid law enforcement,” said Dr. Stevan Jovanovich, Chief Executive Officer of IntegenX. “His involvement and counsel will be invaluable as we prepare to launch our RapidHIT™ 200 Human Identification System in the U.S. and globally.”

The IntegenX RapidHIT 200 is a mobile, self-contained Human Identification (HID) system that automates and accelerates the process of producing standardized DNA profiles from mouth swabs and other human samples in less than 90 minutes. Numerous local, state, national, and international law enforcement and security agencies use DNA-based human identification to make informed identification decisions regarding the arrest, detention, or release of suspects, as well as to analyze crime scene evidence. The RapidHIT 200 system will allow, for the first time, rapid DNA analysis at the point of collection — such as on arrest or detention — setting a new standard in the usage of DNA profiles as an actionable biometric similar to fingerprints.

IntegenX™ Raises $40 Million Financing to Speed Commercialization of Rapid Human DNA Identification System

RapidHIT™ 200 to Create New Market for Real-time DNA Identification

Pleasanton, California – December 13, 2011 – IntegenX Inc., the leading developer of rapid human DNA identification technology and DNA sequencing library preparation systems, has secured $40 Million in Series C funding to accelerate development of the company’s product pipeline and the commercialization of its RapidHIT™ 200 Human Identification System into domestic and international markets. Industry observers expect this product to be disruptive and that it will create a new market for rapid analysis of human DNA for real-time biometric identification. New investor Essex Woodlands, a leading healthcare growth equity and venture capital firm, led the financing round and joins existing investors Domain Associates, QuestMark Partners, Greenspring Associates, Cross Creek Capital, RONAholdings LLC, Samsung Ventures, and strategic partner In-Q-Tel. Joining the company’s Board of Directors are Ronald Eastman of Essex Woodlands and Benjamin S. Schapiro of QuestMark Partners.

The RapidHIT 200 is a breakthrough sample-to-profile biometric system that will enable law enforcement, government agencies, and forensic laboratories worldwide to reliably and accurately provide real-time human DNA analysis. The system is the first fully automated DNA identification technology capable of producing DNA profiles from buccal swabs or other human samples in less than 90 minutes. The RapidHIT 200 will allow DNA analysis at the point of collection, such as an arrest or detention, setting a new standard in the usage of DNA profiles as an actionable biometric. By contrast, human DNA samples currently must be transported or shipped to laboratories that rely on highly trained technicians using multiple instruments for analyses taking 10 to14 hours, with access to results delayed up to 30 days or more. Already tested in multiple environments including field, office, and laboratory locations, the RapidHIT 200 and consumables system is expected to launch in the US and abroad through the first six months of 2012.

Stevan Jovanovich, Ph.D., chief executive officer of IntegenX, offered that, “The syndicate created by Essex Woodlands and our existing investors has provided significant financial resources to strengthen our commercial capabilities and successfully market a sample-to-answer system that establishes a new standard in human DNA identification. The RapidHIT 200 technology is compelling in that it will open up new markets by providing easy to use DNA profiling capabilities not available today. Clearly central to the financing was the vision of providing law enforcement, homeland security and military agencies with a system that will revolutionize the usage of human DNA identification.”

According to Essex Woodlands managing director Ronald Eastman, “The management team at IntegenX has an impressive development and commercial track record. We believe that these qualifications coupled with a competitive position in a disruptive technology provide a foundation from which IntegenX can become a leader in rapid human DNA identification.”

IntegenX’s Commercial Product Lines:
The Apollo 324™ is an automated platform that relieves the next-generation sequencing bottleneck in DNA and RNA library preparation. The system makes routine the preparation of up to 32 libraries per day by significantly decreasing the most laborious aspects of the process. IntegenX is the only company to offer an automated library preparation system that supports the major next-generation sequencers and offers a selection of optimized platform-specific library preparation reagent kits.

GenTegra™ and GenPlate® products stabilize DNA, RNA, whole blood, and biological fluids, allowing dry-state room temperature storage with essentially no degradation. They uniquely facilitate storage and shipment of biological samples without the need for refrigeration, freezing, or dry ice.

About Essex Woodlands
With $2.5 billion under management, Essex Woodlands is one of the largest and oldest growth equity and venture capital firms pursuing investments in pharmaceuticals, biotechnology, medical devices, life science tools, health care services and health information technology. Since its founding in 1985, Essex Woodlands has been involved in the founding, investing, and/or management of over 100 healthcare companies ranging across all sectors, stages and geography. The team is comprised of 25 senior investment professionals with offices in Palo Alto, Houston, New York and London. For more information, please see www.ewhv.com.